| 000 | 01146 a2200337 4500 | ||
|---|---|---|---|
| 005 | 20250515235343.0 | ||
| 264 | 0 | _c20101202 | |
| 008 | 201012s 0 0 eng d | ||
| 022 | _a1179-1950 | ||
| 024 | 7 |
_a10.2165/11538000-000000000-00000 _2doi |
|
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _aSharac, Jessica | |
| 245 | 0 | 0 |
_aPharmacoeconomic considerations in the treatment of multiple sclerosis. _h[electronic resource] |
| 260 |
_bDrugs _cSep 2010 |
||
| 300 |
_a1677-91 p. _bdigital |
||
| 500 | _aPublication Type: Journal Article; Review | ||
| 650 | 0 | 4 |
_aAdjuvants, Immunologic _xeconomics |
| 650 | 0 | 4 | _aCost of Illness |
| 650 | 0 | 4 | _aEconomics, Pharmaceutical |
| 650 | 0 | 4 | _aGlatiramer Acetate |
| 650 | 0 | 4 | _aHumans |
| 650 | 0 | 4 | _aInterferon beta-1a |
| 650 | 0 | 4 | _aInterferon beta-1b |
| 650 | 0 | 4 |
_aInterferon-beta _xeconomics |
| 650 | 0 | 4 |
_aMultiple Sclerosis _xdrug therapy |
| 650 | 0 | 4 |
_aPeptides _xeconomics |
| 700 | 1 | _aMcCrone, Paul | |
| 700 | 1 | _aSabes-Figuera, Ramon | |
| 773 | 0 |
_tDrugs _gvol. 70 _gno. 13 _gp. 1677-91 |
|
| 856 | 4 | 0 |
_uhttps://doi.org/10.2165/11538000-000000000-00000 _zAvailable from publisher's website |
| 999 |
_c20066867 _d20066867 |
||